Bio-Optronics Receives $30M Growth Investment

Bio-Optronics, a Rochester, NY-based provider of software to healthcare organizations, received a $30m investment from Mainsail Partners.

Mainsail will partner with the Chief Executive Officer, Dan Kerpelman, and the existing management team to scale the business. In conjunction with the investment, Michael Anderson, Partner at Mainsail Partners, Taylor McKinley, Operating Partner at Mainsail, and David Farsai, Vice President at Mainsail, will join Bio-Optronics’ Board of Directors.

The company will use the capital to accelerate product development, enhance customer service, and grow sales and marketing.

Bio-Optronics creates user-focused applications for healthcare organizations with applications focused on clinical research, automated resource utilization and patient safety. It provides:
– Clinical Conductor, a Clinical Trial Management System (CTMS),
– Momentum, which enables fast, automated and accurate medical staff scheduling, and
– Biopoint, which enhances patient safety and streamlines patient workflow.

Customers include leading hospital systems, clinical research sites and organizations, medical groups, and the Department of Veterans Affairs.



Join the discussion